Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Liver Neoplasms × Drug Evaluation × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Hypogonadism 1 Fatigue Syndrome, Chronic 1 Fallopian Tube Neoplasms 1 Eunuchism 1 Carcinoma, Ovarian Epithelial 1

Interventions

Bevacizumab 10 pembrolizumab 5 durvalumab 5 atezolizumab 5 lenvatinib 4 tremelimumab 3 fludarabine 3 camrelizumab 3 apatinib 3 Ipilimumab 3 Cyclophosphamide 3 regorafenib 2 Riluzole 2 Radiotherapy 2 Nivolumab 2 Magnetic Resonance Imaging 2 Idarubicin 2 Blood Specimen Collection 2 Biopsy 2 yttrium chloride 1 trastuzumab deruxtecan 1 toripalimab 1 spartalizumab 1 sintilimab 1 pertuzumab 1 fludarabine phosphate 1 ferric carboxymaltose 1 epigallocatechin gallate 1 donafenib 1 brodalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05913141 2023-06-22

PDO/PDO-TIL/PDOTS for Drug Screen

Shanghai Zhongshan Hospital

Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡